JAKARTA-2 Reanalysis Demonstrates Activity With Fedratinib in Myelofibrosis After Ruxolitinib Failure
Ruben Mesa, MD, discusses the results from a reanalysis of the phase II JAKARTA-2 study in patients with myelofibrosis (MF) who received a previous treatment of ruxolitinib (Jakafi) and failed treatment.
Ruben Mesa, MD, director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the results from a reanalysis of the phase II JAKARTA-2 study in patients with myelofibrosis (MF) who received a previous treatment of ruxolitinib (Jakafi) and failed treatment.
The JAKARTA-2 trial was conducted several years ago, looking at the investigational JAK2 inhibitor fedratinib as treatment of patients with MF after ruxolitinib failure. After ruxolitinib was approved by the FDA, however, investigators found that the criteria for ruxolitinib intolerance or resistance needed to be updated. The criteria did not fully capture the activity of fedratinib, says Mesa.
With 8 years of experience in this patient population, investigators reevaluated the criteria to include minimums of 3 months on ruxolitinib therapy, amount of spleen growth, symptoms, cytopenias, and other criteria. In the reanalysis, Mesa says just under 70 patients were evaluated for efficacy with at least 6 months of fedratinib therapy.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
